Who owns PRELUDE THERAPEUTICS INC?

Tip: Access positions for across all investors

Analyze quarterly positions in Prelude Therapeutics with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Prelude Therapeutics stock

Who bought or sold PRELUDE THERAPEUTICS INC this quarter?

Fund or Company Name Shares Held Valued At Change in Shares As Of Actions
OrbiMed Advisors 11M $52M 0% Mar 2024
 View chart
Baker Bros. Advisors 10M $48M 0% Mar 2024
 View chart
Deerfield Management Company 4.1M $20M 0% Mar 2024
 View chart
Boxer Capital 2.6M $12M 0% Mar 2024
 View chart
BlackRock 1.1M $5.2M 3% Mar 2024
 View chart
Vanguard Group 1.0M $4.8M 1% Mar 2024
 View chart
T. Rowe Price Associates 942k $4.5M -10% Mar 2024
 View chart
Massachusetts Financial Services 508k $2.4M -1% Mar 2024
 View chart
Geode Capital Management 362k $1.7M 9% Mar 2024
 View chart
Sio Capital Management 320k $1.5M -8% Mar 2024
 View chart
Morgan Stanley 296k $1.4M 21% Mar 2024
 View chart
TD Asset Management 161k $762k 0% Mar 2024
 View chart
Charles Schwab Investment Management 127k $604k 2% Mar 2024
 View chart
Bridgeway Capital Management 124k $586k 235% Mar 2024
 View chart
Northern Trust 122k $579k 6% Mar 2024
 View chart
Millennium Management 102k $483k 5% Mar 2024
 View chart
Two Sigma Advisers 70k $333k 14% Mar 2024
 View chart
Goldman Sachs Group 67k $320k -3% Mar 2024
 View chart
Exchange Traded Concepts 64k $303k 45% Mar 2024
 View chart
Two Sigma Investments 61k $287k 4% Mar 2024
 View chart
Bank of New York Mellon 40k $190k -21% Mar 2024
 View chart
HPM Partners 33k $154k 100% Mar 2024
 View chart
Bank of America Corporation 32k $153k -14% Mar 2024
 View chart
Citadel Advisors 30k $142k -69% Mar 2024
 View chart
Kennedy Capital Management 25k $119k 100% Mar 2024
 View chart
Hsbc Holdings 23k $94k 0% Dec 2023
 View chart
Acadian Asset Management 22k $104k 215% Mar 2024
 View chart
Rhumbline Advisers 21k $100k 4% Mar 2024
 View chart
Barclays 20k $97k -33% Mar 2024
 View chart
New York State Common Retirement Fund 20k $95k 0% Mar 2024
 View chart
Connor, Clark & Lunn Investment Management 20k $95k 100% Mar 2024
 View chart
State of Wisconsin Investment Board 20k $93k -21% Mar 2024
 View chart
Zacks Investment Management 19k $88k 100% Mar 2024
 View chart
Nuveen Asset Management 17k $80k 22% Mar 2024
 View chart
Jane Street 16k $78k -50% Mar 2024
 View chart
Walleye Trading Advisors 16k $78k 100% Mar 2024
 View chart
UBS Group 16k $74k -21% Mar 2024
 View chart
Amundi 15k $52k 0% Mar 2024
 View chart
Dimensional Fund Advisors 14k $68k 0% Mar 2024
 View chart
Springbok Capital Management 14k $66k 100% Mar 2024
 View chart
FMR 12k $55k -100% Mar 2024
 View chart
American International 7.4k $32k 4% Dec 2023
 View chart
Jpmorgan Chase & Co 6.2k $30k -33% Mar 2024
 View chart
Wells Fargo & Company 5.3k $25k 15% Mar 2024
 View chart
Tower Research Capital 3.3k $16k -4% Mar 2024
 View chart
Citigroup 2.8k $13k 32% Mar 2024
 View chart
Royal Bank of Canada 2.1k $0 -77% Mar 2024
 View chart
California State Teachers Retirement System 1.5k $7.1k -52% Mar 2024
 View chart
Legal & General Group 962.00 $4.6k 0% Mar 2024
 View chart
Summit Investment Advisors 819.00 $3.9k 0% Mar 2024
 View chart
Amalgamated Bank 334.00 $2.0k -61% Mar 2024
 View chart
HighMark Wealth Management 50.00 $237.000000 0% Mar 2024
 View chart
CWM 2.00 $0 100% Mar 2024
 View chart
Nelson, Van Denburg & Campbell Wealth Management 1.00 $4.000000 100% Mar 2024
 View chart

Who sold out of Prelude Therapeutics?

Fund or Company Name Date Sold Shares Held Valued At
Woodline Partners Sep 2023 200k $618k
Jacobs Levy Equity Management Dec 2023 131k $561k
Squarepoint Ops Dec 2023 29k $126k
Virtu Financial Dec 2023 14k $58k
SG Americas Securities Dec 2023 13k $56k
Simplex Trading Dec 2023 67.00 $0